Analyst Reco. 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
24.9 ^USD	-0.99%		-4.23%	+22.90%

May. 15	Transcript : 4D Molecular Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
May. 09	4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	Apr. 15	MT
RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier	Apr. 15	MT
4D Molecular Therapeutics Insider Sold Shares Worth $259,102, According to a Recent SEC Filing	Apr. 04	MT
BMO Capital Cuts 4D Molecular Therapeutics' Price Target to $63 From $70, Keeps Outperform Rating	Apr. 01	MT
Jefferies Raises 4D Molecular Therapeutics' Price Target to $58 From $30, Maintains Buy Rating	Apr. 01	MT
BMO Capital Adjusts 4D Molecular Therapeutics' Price Target to $70 From $50, Keeps Outperform Rating	Feb. 05	MT
Powell Comments Dampen Near-Term Rate Cut Hopes, Stifling US Equity Futures Pre-Bell	Feb. 05	MT
RBC Raises PT on 4D Molecular Therapeutics to $35 From $25, Keeps Outperform Rating, Speculative Risk	Feb. 05	MT
Chardan Ups Price Target on 4D Molecular Therapeutics to $31 From $30, Maintains Buy Rating	23-07-11	MT
Chardan Initiates 4D Molecular Therapeutics With Buy Rating, $30 Price Target	23-07-05	MT
BofA Adjusts Price Target on 4D Molecular Therapeutics to $33 From $28, Keeps Buy Rating	23-06-08	MT
SVB Securities Trims Price Target on 4D Molecular Therapeutics to $13 From $14, Keeps Market Perform Rating	23-04-13	MT
SVB Securities Adjusts Price Target on 4D Molecular Therapeutics to $14 From $15, Maintains Market Perform Rating	23-02-06	MT
BMO Capital Starts 4D Molecular Therapeutics at Outperform With $50 Price Target	23-01-30	MT
HC Wainwright Starts 4D Molecular Therapeutics at Buy With $36 Price Target	22-11-18	MT
Goldman Sachs Upgrades 4D Molecular Therapeutics to Buy From Neutral, Raises Price Target to $68 From $12	22-11-15	MT
SVB Securities Raises 4D Molecular Therapeutics' Price Target to $15 From $11, Keeps Market Perform Rating	22-11-14	MT
Evercore ISI Adjusts 4D Molecular Therapeutics Price Target to $45 From $32, Maintains Outperform Rating	22-11-14	MT
SVB Securities Adjusts Price Target on 4D Molecular Therapeutics to $11 From $10, Maintains Market Perform Rating	22-11-10	MT
SVB Securities Downgrades 4D Molecular Therapeutics to Market Perform From Outperform Rating, Adjusts Price Target to $12 From $28	22-08-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Analyst Reco.

Filters